Pulmonx (LUNG) Q4 2025: Operating Expenses Cut 10% as U.S. Sales Force Rebuilds for Back-Half Rebound
Pulmonx enters 2026 with a streamlined cost base and renewed commercial discipline after a year marked by U.S. sales disruption and internal missteps. Management’s focus has pivoted to reestablishing sales force stability, realigning strategic priorities, and accelerating clinical programs like AeroSeal to expand the addressable market. Investors should watch for execution on U.S. sales ramp and margin leverage as Pulmonx targets a return to growth in the second half of the year.
Summary
- Cost Structure Realignment: Operating expenses reduced by over 10%, freeing resources for targeted growth programs.
- U.S. Sales Force Stabilization: Nearly all open sales positions filled after disruptive turnover and incentive misalignment in 2025.
- Back-Half Growth Inflection: Management expects U.S. and international sales to reaccelerate in the second half as new reps ramp and China resumes orders.
Performance Analysis
Pulmonx’s Q4 2025 results reflected the lingering impact of U.S. sales force turnover and operational missteps, with total revenue declining year-over-year and U.S. sales down double digits. The U.S. business, which constitutes the majority of company revenue, was hampered by a misaligned incentive structure and territory disruption, leading to roughly 50% turnover in the sales organization across the year. International revenue, while up in Europe, was partially offset by a pause in China distributor sales due to regulatory renewal delays. Gross margin improved due to a lower mix of lower-margin distributor sales, but the company’s top-line softness weighed on overall profitability.
Operating expenses declined meaningfully as Pulmonx executed a cost restructuring, with most reductions coming from G&A and marketing while preserving investment in commercial and R&D priorities. Annual cash burn is guided to drop nearly 30% in 2026, reflecting a sharper focus on financial discipline. The company’s new $60 million credit facility extends debt maturity and provides additional liquidity, supporting ongoing clinical and commercial investments.
- Margin Expansion: Gross margin improved to 77.6% in Q4, benefiting from a favorable sales mix.
- Expense Reduction: Total operating expenses fell 11% in Q4, with further decreases planned for 2026.
- Cash Runway Strengthened: Debt refinancing and lower burn extend Pulmonx’s financial flexibility through key growth initiatives.
The company’s path to profitability now depends on the successful ramp of its rebuilt U.S. sales force, the execution of its streamlined commercial strategy, and the progress of its AeroSeal clinical program.
Executive Commentary
"Our top three priorities are clear. First, re-accelerating U.S. sales growth, second, advancing our TAM expanding clinical initiatives, and third, aligning our spending to deliver continued financial leverage as we move predictably toward profitability."
Glenn French, President and Chief Executive Officer
"We recently executed a cost restructuring initiative that reduced our ongoing operating expenses by over 10%. With this action, we believe we have achieved an appropriate balance between expense management and continued investment in our key growth initiatives."
Derek Sung, Chief Operating Officer and Chief Financial Officer
Strategic Positioning
1. U.S. Sales Force Rebuild and Focused Commercial Execution
Pulmonx is prioritizing the stabilization and productivity of its U.S. sales force, following a year where territory misalignment and poorly designed incentives led to high turnover and lost momentum. The company has now filled nearly all open positions, implemented a senior-junior rep pairing for faster onboarding, and reverted to proven incentive structures. The commercial focus is now on high-impact physician engagement and supporting established treating centers, abandoning low-return distractions.
2. Streamlined Organizational Structure and Cost Discipline
Leadership has reduced direct reports and reallocated resources to critical functions, enabling sharper focus on sales, clinical operations, and expense control. The 10% operating expense reduction was achieved mainly through cuts in G&A and marketing, preserving investment in sales and R&D. This positions Pulmonx to demonstrate operating leverage as revenue growth returns.
3. Pipeline Acceleration with AeroSeal and Clinical Expansion
The AeroSeal program, aimed at severe COPD patients with collateral ventilation, is positioned as a medium- to long-term growth driver. Recent clinical leadership changes have accelerated enrollment in the pivotal CONVERT-2 trial, which, if successful, could expand Pulmonx’s global addressable market by an estimated 20%. Enrollment completion is targeted for 2027, with incremental revenue opportunity anticipated thereafter.
4. International Market Dynamics and Channel Timing
International revenue growth is expected to be back-half weighted, with ongoing strength in Europe and a resumption of China distributor sales as regulatory hurdles clear. Japan remains a small contributor in 2026 as its post-approval study continues, with more meaningful impact expected in future years.
Key Considerations
Pulmonx’s 2026 outlook hinges on executing a turnaround in U.S. commercial productivity and leveraging its leaner cost base for improved margin trajectory. The company’s discipline in focusing on proven sales strategies and targeted clinical expansion will be tested as new reps ramp and market conditions evolve.
Key Considerations:
- Sales Force Ramp Timeline: Management expects 6-9 months for new reps to reach full productivity, with a linear improvement in U.S. sales through 2026.
- Incentive Plan Reset: After a misstep in 2025, the company has reverted to historically effective quota allocation and compensation frameworks to retain and motivate talent.
- China and Japan Revenue Timing: China sales are expected to resume in the second half, while Japan remains a modest contributor until full commercialization in later years.
- AeroSeal Investment: Clinical trial costs are manageable and will not constrain commercial investments, with trial enrollment now accelerating under new leadership.
Risks
Pulmonx faces execution risk in rebuilding its U.S. sales force and restoring lost momentum, particularly given the lag time for new reps to become fully productive. International revenue is exposed to regulatory and distributor timing, especially in China. Competitive activity in the pulmonary space is rising, and any further disruption in clinical trial progress or reimbursement could pressure the growth thesis. Management’s guidance assumes a smooth ramp in both commercial and clinical execution, which may prove optimistic if macro or internal challenges persist.
Forward Outlook
For Q1 and the first half of 2026, Pulmonx guided to:
- Continued U.S. sales declines in the first half, improving to growth in the back half as new reps ramp up.
- Minimal China distributor sales in H1, with a return to shipments in H2 upon certificate renewal.
For full-year 2026, management maintained guidance:
- Revenue in the range of $90 to $92 million, with growth returning in both U.S. and international businesses in the second half.
- Gross margin of approximately 75%, with some mix-driven variability between halves.
- Operating expenses (ex-stock comp) to decline 7-9% versus 2025, reflecting ongoing cost discipline.
Management highlighted several factors that will shape the year:
- Sales force productivity ramp and retention will be the key determinant of U.S. growth trajectory.
- China and international timing will drive optical revenue swings, but underlying European strength remains steady.
Takeaways
Pulmonx’s 2026 will be defined by execution on a rebuilt U.S. sales force, disciplined cost management, and the early returns from a refocused commercial strategy.
- Execution Pivot: The company’s operational reset and focus on proven commercial levers is designed to restore stability and growth after a turbulent 2025.
- Margin and Cash Leverage: With expenses structurally lower and cash runway extended, Pulmonx is positioned to benefit disproportionately from top-line recovery.
- Clinical and Market Expansion: AeroSeal’s progress and international channel timing will be critical for medium-term upside, while U.S. sales force productivity is the near-term watchpoint.
Conclusion
Pulmonx’s Q4 and full-year 2025 results reflect a company in transition, with decisive leadership actions to address internal missteps and restore growth. Investors should monitor the pace of U.S. sales force ramp, cost leverage, and clinical program milestones as the company seeks to reestablish its growth trajectory and deliver sustainable profitability.
Industry Read-Through
Pulmonx’s experience highlights the critical importance of sales force stability and incentive alignment in medtech commercial models, especially when launching new programs or expanding call points. The company’s disciplined cost reset and focus on high-ROI clinical and commercial investments provide a template for peers facing growth slowdowns or execution drift. The delayed but not canceled China revenue underscores the need for nuanced international channel management in regulated markets. Pulmonx’s AeroSeal trial progress and TAM expansion efforts signal that clinical pipeline execution remains a key lever for long-term value creation across the pulmonary and interventional device landscape.